Cargando…

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond

Detalles Bibliográficos
Autores principales:	Ascierto, Paolo A., Marincola, Francesco M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	In Focus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485477/ https://www.ncbi.nlm.nih.gov/pubmed/26137543 http://dx.doi.org/10.1016/j.ebiom.2015.01.011

Ejemplares similares

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Inflammatory and autoimmune predictive markers of response to anti-PD-1/PD-L1 therapy in NSCLC and melanoma
por: Musaelyan, Aram A., et al.
Publicado: (2022)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
por: Spagnolo, Francesco, et al.
Publicado: (2021)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
por: Botti, Gerardo, et al.
Publicado: (2017)

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
por: Lu, Di, et al.
Publicado: (2019)

Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
por: Tabana, Yasser, et al.
Publicado: (2021)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1
por: Liu, Nian, et al.
Publicado: (2023)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
por: Cristinziano, Leonardo, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
por: Ribas, Antoni, et al.
Publicado: (2020)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
por: Mishra, Surbhi, et al.
Publicado: (2022)

PD‐L1 and beyond: Immuno‐oncology in cytopathology
por: Iaccarino, Antonino, et al.
Publicado: (2021)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
por: Chrétien, Sebastian, et al.
Publicado: (2019)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
por: Xu, Jun, et al.
Publicado: (2021)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
por: Veerman, Rosanne E., et al.
Publicado: (2023)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021)

An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
por: Beaver, Julia A., et al.
Publicado: (2018)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
por: Ascierto, Paolo A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jp7hinlrrnb3b4364q0dena8o8